NCT05540964View on ClinicalTrials.gov

An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy

UnknownOBSERVATIONAL
Enrollment

7

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

July 19, 2025

Study Completion Date

July 19, 2025

Conditions
HIV
Interventions
OTHER

Antiretroviral Therapy Interruption(ATI)

Study participant that were previously infused with autologous genetically modified cell product will be taken off ART and followed closely by monitoring HIV rebound.

Trial Locations (2)

20007

Georgetown University, Washington D.C.

20017

Washington Health Institute, Washington D.C.

Sponsors
All Listed Sponsors
lead

American Gene Technologies International Inc.

INDUSTRY

NCT05540964 - An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy | Biotech Hunter | Biotech Hunter